CNS Candidates Mostly Offer New Approaches In Established Categories
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CNS candidates range from new mechanisms in multiple sclerosis to the first orexin antagonist for insomnia and refinements in neurotransmitter targeting for schizophrenia and depression. A second amyloid imaging agent could reach the market to aid in diagnosis of Alzheimer’s disease.